Pharmaceutical intermediates
Eltrombopag Intermediates
6 pharmaceutical intermediates for Eltrombopag. Indication: Aplastic Anemia; Idiopathic Thrombocytopenic Purpura (ITP); Hepatitis C; Chronic Hepatitis C.
About Eltrombopag
- Originator
- Glaxosmithkline (Gsk)
- Indication
- Aplastic Anemia; Idiopathic Thrombocytopenic Purpura (ITP); Hepatitis C; Chronic Hepatitis C
- Approved Date
- 11/29/2023
- DS/DP
- 11/05/2038
Available intermediates
6 intermediates currently listed for Eltrombopag. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 3'-aMino-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid hydrochloride | 376591-97-8 | / | / |
| 1-(3,4-DIMETHYLPHENYL)-3-METHYL-3-PYRAZOLIN-5-ONE | 18048-64-1 | / | / |
| 2-HYDROXY-3''-NITRO-BIPHENYL-3-CARBOXYLIC ACID | 376591-95-6 | / | / |
| 3-bromo-2-methoxyaniline | 116557-46-1 | / | / |
| 3''-AMINO-2''-HYDROXY-BIPHENYL-3-CARBOXYLIC ACID | 376592-93-7 | / | / |
| 2-(3,4-Dimethylphenyl)-1,2-dihydro-5-methyl-3H-pyrazol-3-one | 277299-70-4 | / | / |
Building toward Eltrombopag?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →